29 results about "Antibiotic combinations" patented technology

The invention discloses a single-cell probiotic packaging method of thiolated guluronic acid oligosaccharide and a probiotic microcapsule, and relates to the technical field of biological medicines. The packaging method comprises the following steps: mixing a thiolated guluronic acid oligosaccharide solution with a probiotic suspension to form a probiotic-polysaccharide mixed solution; and adding a calcium chloride solution into the probiotic-polysaccharide mixed solution, and stirring to form the single-cell microcapsule encapsulating the probiotics. The packaging method can protect a single strain from being damaged by an external adverse environment to the maximum extent, and the survival rate is increased. Meanwhile, the obtained single-cell microcapsule can improve the digestion of the probiotics, the survival rate of the probiotics under the oxidative stress environment and the antibiotic combination, has high stability, and prolongs the intestinal residence time of the probiotics. An innovative solution is provided for the problems that in the existing medicine field, probiotic preparations cannot improve the gastrointestinal stress resistance of probiotics, and antibiotics lose efficacy when combined.

The present invention belongs to the technical field of biomedicine, and relates to use of linoleic acid in the preparation of a drug for improving the sensitivity of Gram-positive bacteria to an antibiotic. It has been discovered for the first time that the combined use of linoleic acid and an antibiotic can significantly improve the sensitivity of Gram-positive bacteria to the antibiotic. In vivo study data have shown that the combination of linoleic acid and the antibiotic can not only improve the survival rate of mice infected with Gram-positive bacteria, but also enhance the ability of the mice to clear Gram-positive bacteria. Furthermore, formulating linoleic acid and the antibiotic into an anti-infection composition can, in one aspect, achieve a significant clinical anti-infection effect, and in another aspect, prolong the post-antibiotic effect. Moreover, linoleic acid is an essential fatty acid in human and animal nutrition, with high nutritional value, and it has been widely used in food and pharmaceutical products, demonstrating high safety.

The present invention relates to an antimicrobial composition of a penicillin, a β-lactamase inhibitor and an ion-chelating agent. More particularly, the present invention relates to an antibiotic composition of piperacillin, avibactam and EDTA in a predefined ratio for the effective management of bacterial infections by decreasing the MIC and increasing the stability of the composition.

The invention provides a composition (e.g., pharmaceutical composition) comprising a combination of two or more phages, wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The invention provides a method of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal comprising administering a pharmaceutical composition comprising a combination of two or more phages wherein the phages are two or more of: (a) phage D29; (b) phage AdephagiaΔ41Δ43; (c) phage FionnbharthΔ47; (d) phage Fred313cpm-1; and (e) phage MuddyHRMN0052-1; and a pharmaceutically acceptable carrier. The composition can be administered alone or in combination with one or more antibiotics, wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

The invention belongs to the technical field of biological medicines, and in particular relates to an application of hyssopus rigidus var. Cupidus essential oil in preparation of an antibiotic antibacterial sensitizer and / or preparation of an antibiotic combined medicine, and further relates to an application of the hyssopus rigidus var. Cupidus essential oil in preparation of the antibiotic antibacterial sensitizer and / or the antibiotic combined medicine. It is found that the hyssop officinalis essential oil can enhance the antibacterial sensitivity of various antibiotics including fluconazole and amphotericin B, the hyssop officinalis essential oil and the antibiotics are combined for use, the synergistic antibacterial activity is achieved, and the better antibacterial effect is achieved while the dosage of the antibiotics is reduced; important technical support is provided for improving the current situation of drug resistance of fungi.

The invention belongs to the technical field of biological medicines, and particularly relates to application of linoleic acid in preparation of a medicine for improving sensitivity of gram-positive bacteria to antibiotics. It is found for the first time that combination of linoleic acid and antibiotics can significantly improve the sensitivity of gram-positive bacteria to antibiotics; in-vivo research data shows that the combination of linoleic acid and antibiotics not only can improve the survival rate of mice infected with gram-positive bacteria, but also can improve the ability of mice to remove gram-positive bacteria; linoleic acid and antibiotics are further prepared into the anti-infection composition, on one hand, the remarkable clinical anti-infection effect can be achieved, and on the other hand, the post-effect of the antibiotics can be prolonged; moreover, the linoleic acid is a necessary fatty acid in nutrition of human bodies and animals, is high in nutritional value, is widely applied to food and medicines, and is high in safety.

The application belongs to the technical field of biological medicine, and discloses application of Ebselen as a synergist of polymyxin in inhibition of salmonella. It is found that Ebselen combined with polymyxin has good synergistic effect on salmonella in vitro and in vivo experiments. In a mouse salmonella infection model, the bacterial load in the liver of animals treated with EBS combined with polymyxin is significantly lower than that treated with single drug. The survival rate of animals treated with EBS combined with polymyxin is significantly higher than that treated with EBS and polymyxin alone. Compared with traditional antibiotics and antibiotic combination to kill salmonella, the synergistic bactericidal effect of Ebselen and polymyxin is less likely to induce bacterial drug resistance, and Ebselen has the characteristics of wide source, multiple effects and good treatment effect, which has good research and application significance for exploring antibiotic synergistic replacement and solving bacterial drug resistance.

The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.

This description provides injectable antibiotic compositions for veterinary use. The compositions are characterized by forming a gel at physiological animal temperature, and this gel exhibits a stable and repeatable antibiotic release profile. The compositions comprise a high drug load in poloxamer solutions with the addition of a cosolvent, and preferably with the addition of a cellulose derivative at least partially soluble in organic solvents. Methods for treating veterinary infections are also provided.

An antibiotic composition contains, as an active ingredient, a diatomaceous earth-zinc oxide composite comprising zinc oxide on diatomaceous earth, and an antifungal combination preparation contains a diatomaceous earth-zinc oxide composite including zinc oxide on diatomaceous earth and an antifungal agent. The antibiotic composition is less toxic while exhibiting excellent antibiotic activity, for example, antiviral, antibacterial or antifungal activity. The antibiotic composition is usable to prevent contamination or infection by viruses, bacteria or fungi, inhibit the growth of viruses, bacteria or fungi, or treat infections by viruses, bacteria or fungi.

Provided is a use of a combined composition in preparing a drug for resisting fungal and bacterial infections. Active components of the combined composition are an antibiotic and an antibiotic adjuvant, wherein the antibiotic adjuvant is celastrol or a pharmaceutical salt thereof. The present application creatively discovers that celastrol or the pharmaceutical salt thereof can be combined with the antibiotic and the combination has a very excellent effect in resisting the fungal and bacterial infections, especially in resisting the fungal infections. Celastrol or the pharmaceutical salt thereof can enhance an antimicrobial effect of the antibiotic, especially an antifungal effect of the antibiotic, significantly increasing an antimicrobial sensitivity of the antibiotic and inhibiting the occurrence of fungal or bacterial drug-resistance. As an antibiotic adjuvant-antibiotic drug platform, the combined composition provides a new strategy for achieving an efficient antimicrobial effect, and the application dosage forms and the application scenarios are very diverse.

The invention relates to a sepsis diagnosis and treatment scheme recommendation method based on reinforcement learning and clinical knowledge, and the method comprises the steps: firstly modeling an antibiotic combination use problem in a sepsis treatment process into a Markov decision process, and constructing a model through DQN; secondly, deep reinforcement learning based on a value function is combined with sepsis clinical data and medical guideline related content, clinical real data are referred to in a reward function, SOFA scoring knowledge and clinical guideline content are fused, and the model is guided to conduct strategy recommendation in the direction of reasonably shortening antibiotic medication duration and ensuring good prognosis of a patient. According to the constructed model, patient demographic characteristics, basic vital signs, microbial culture results and antibiotic use data serve as model input, four reward functions are constructed in combination with clinical priori knowledge, clinical data and medical guide guidance, the medical interpretability and clinical consistency of SAI-DQN are enhanced, and the method is suitable for clinical application and popularization. And the SAI-DQN is utilized to provide personalized antibiotic combined treatment suggestions for the sepsis patients.

The present invention provides antibiotic combination therapies for treating Acinetobacter baumannii infection in a subject. These combination therapies comprise rifudine and a second antibiotic such as colistin and cefdinir.

Disclosed herein in some aspects are a polysaccharide-coated liposome and a composition comprising the polysaccharide-coated liposome and a pharmaceutically acceptable carrier or excipient. In some embodiments, disclosed herein is a chitosan-coated liposome with lysozyme-responsive properties for on-demand release of an antibiotic encapsulated therein in a lysozyme-rich environment while maintaining the stability of the liposome in a lysozyme-deficient environment.

The invention belongs to the technical field of biological medicines, and particularly relates to application of linoleic acid in preparation of a medicine for improving sensitivity of gram-positive bacteria to antibiotics. It is found for the first time that combination of linoleic acid and antibiotics can significantly improve the sensitivity of gram-positive bacteria to antibiotics; in-vivo research data shows that the combination of linoleic acid and antibiotics not only can improve the survival rate of mice infected with gram-positive bacteria, but also can improve the ability of mice to remove gram-positive bacteria; linoleic acid and antibiotics are further prepared into the anti-infection composition, on one hand, the remarkable clinical anti-infection effect can be achieved, and on the other hand, the post-effect of the antibiotics can be prolonged; moreover, the linoleic acid is a necessary fatty acid in nutrition of human bodies and animals, is high in nutritional value, is widely applied to food and medicines, and is high in safety.

An antibiotic therapeutic composition or method of treatment includes administering a beta-lactamase inhibitor in combination with a beta-lactam antibiotic. The beta-lactamase inhibitor can be a boronic-acid, a boronic-ester beta-lactamase inhibitor, carboxyl-group beta-lactamase inhibitors, halogen-terminated heterocyclic group beta-lactamase inhibitors, or any pharmaceutically acceptable salts thereof. In combination, the beta-lactamase inhibitors and beta-lactam antibiotics can inhibit the growth of bacteria that are resistant to the beta-lactam antibiotics alone. According to additional embodiments, the effectiveness of various combinations of compounds including various antibiotics and compounds selected from the group consisting of 5-Carboxythiophene-2-boronic acid pinacol ester, 5-Carboxy-2-fluorophenylboronic Acid, 3-Amino-5-carboxylphenylboronic acid, 5-Carboxy-2-chlorophenylboronic acid, 3-Carboxy-2-fluorophenylboronic acid, 5-dehydroxyboryl-2-thiophenecarboxylic acid, and 5-Borono-2-chlorobenzoic acid is demonstrated. Particularly, when combined with certain antibiotics, each of these compounds demonstrates enhanced effectiveness against bacteria and bacterial infections even where the bacteria are known to be resistant to the beta-lactam antibiotics.

This disclosure generally relates to small molecule antibiotic and its novel therapeutic uses for treating bacterial infections, alone or in combination with a secondary antibiotic.

The invention relates to a peptide or peptidomimetic that reduces and / or inhibits activity and / or efficiency of a recombinase. The invention relates to a peptide comprising an amino acid sequence according to X1SPLX2X3L, wherein X1, X2, and X3 are any amino acid, or a peptidomimetic thereof that binds a target site of a recombinase, wherein the peptide or peptidomimetic comprises an alpha helix-like structure and a length of 7 to 15 amino acids. The invention further relates to an in vitro method for modulating recombinase activity and / or efficiency using the peptide or peptidomimetic according to the invention and to a mixture or composition comprising a recombinase and the peptide or peptidomimetic according to the invention. The invention relates further to a peptide or peptidomimetic according to the invention for use in the treatment of patients in need of antimicrobial therapy and to a pharmaceutical composition comprising the peptide or peptidomimetic according to the invention, preferably for combined administration in combination with an antibiotic.

The invention relates to an antibiotic composition comprising or consisting of: a purine nucleoside selected from guanosine and xanthosine, or a combination thereof; and an inhibitor of thymidine and / or pyrimidine biosynthesis. A further combination with a Beta-lactam antibiotic can be provided. The invention further relates to associated kits, methods and uses in treatment.

The invention provides platelet-rich plasma and application of a combination of the platelet-rich plasma and antibiotics in preparation of a medicine for treating equine animal endometritis, and particularly belongs to the technical field of veterinary medicine. The invention provides an application of platelet-rich plasma (PRP) in preparation of a medicine for treating equine animal endometritis. The PRP disclosed by the invention is good in antibacterial effect, has remarkable anti-inflammatory and tissue repair capabilities, and can realize treatment of equine animal endometritis. The combination of the PRP and antibiotics is used for treating infectious donkey endometritis, the antibacterial, anti-inflammatory and tissue repair effects can be synergistically improved, the use amount of the antibiotics and the drug resistance risk are reduced, and the PRP has remarkable comprehensive advantages and clinical application prospects.

The present disclosure provides an antimicrobial composition as well as a process using same to limit microbial activity in a yeast medium. The antimicrobial composition includes at least one weak acid, optionally in combination with an acid stable bacteriocin and / or an antibiotic. The antimicrobial composition can be used for propagating yeasts and for making a fermentation product. The present disclosure also provides yeasts and lactic acid bacteria that can be used with the antimicrobial composition.

The invention discloses a method for purifying cocktail of hydrogen-dependent methylotrophic methanogenic archaea, an obtained purified strain and application of the purified strain. The method comprises the following steps: S1, collecting a sample, sequencing to determine that the sample contains target archaea, and determining whether the target archaea can grow or not; s2, reducing diversity of archaea communities, selecting high-throughput eutrophication, screening substrates and the like, and gradually reducing abundance and concentration of non-target archaea; s3, reducing the diversity of bacterial groups, adding different types of antibiotic combinations and lysozyme, and reducing the diversity of the bacterial groups in combination with gradient dilution culture; and S4, according to the growth stage characteristics of the bacteria and the target archaea, selecting appropriate antibiotics in a continuous interval adding manner, and carrying out gradient dilution passage until the concentration of the bacteria cannot be detected. The invention also provides the hydrogen-dependent methylotrophic methanogenic archaea obtained by the purification method, the preservation number of the methylotrophic methanogenic archaea is CGMCC (China General Microbiological Culture Collection Center) No.46065, and the invention also provides an application of the methylotrophic methanogenic archaea in methane preparation.

The present disclosure relates to antimicrobial compositions, particularly to antibiotic compositions; to methods for identification of antimicrobial compositions involving in silico prediction of antimicrobial activity; and to use of antimicrobial compositions and methods.

The present invention provides a novel compound, a solvate thereof, a hydrate thereof, a prodrug thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an antibiotic composition comprising the same. The novel compound of the present invention having excellent antimicrobial activity is very useful for preventing and treating a bacterial infection.

The invention provides application of vibrio parahaemolyticus lyase LysV569 in preparation of a medicine for splitting vibrio parahaemolyticus. The amino acid sequence of the vibrio parahaemolyticus lyase LysV569 is shown in SEQ ID NO. 1, and the gene sequence of the vibrio parahaemolyticus lyase LysV569 is shown in SEQ ID NO. 2. The lyase can independently penetrate through the outer membrane of gram-negative bacteria without an outer membrane permeabilizing agent, so that the defect that the lyase depends on a chemical adjuvant in the prior art is overcome; under the condition of no permeabilizing agent, the enzyme shows ultrahigh cracking efficiency (the sterilization rate is greater than 99.9% within 1 hour under the concentration of 100 [mu] g / mL, and the CFU is reduced by 4-log) and thermal stability (the activity is maintained to be greater than 99% after 30 minutes of high-temperature treatment at 85 DEG C), and is suitable for scenes of aquaculture pathogen prevention and control, food industry high-temperature sterilization and drug resistance delay by combination of antibiotics. An efficient, environment-friendly and operation-simplified solution is provided for preventing and controlling the food-borne pathogenic bacteria.

An antibiotic therapeutic composition or method of treatment includes administering a beta-lactamase inhibitor in combination with a beta-lactam antibiotic. The beta-lactamase inhibitor can be a boronic-acid, a boronic-ester beta-lactamase inhibitor, carboxyl-group beta-lactamase inhibitors, halogen-terminated heterocyclic group beta-lactamase inhibitors, or any pharmaceutically acceptable salts thereof. In combination, the beta-lactamase inhibitors and beta-lactam antibiotics can inhibit the growth of bacteria that are resistant to the beta-lactam antibiotics alone. According to additional embodiments, the effectiveness of various combinations of compounds including various antibiotics and compounds selected from the group consisting of 5-Carboxythiophene-2-boronic acid pinacol ester, 5-Carboxy-2-fluorophenylboronic Acid, 3-Amino-5-carboxylphenylboronic acid, 5-Carboxy-2-chlorophenylboronic acid, 3-Carboxy-2-fluorophenylboronic acid, 5- dehydroxyboryl-2-thiophenecarboxylic acid, and 5-Borono-2-chlorobenzoic acid is demonstrated. Particularly, when combined with certain antibiotics, each of these compounds demonstrates enhanced effectiveness against bacteria and bacterial infections even where the bacteria are known to be resistant to the beta-lactam antibiotics.

The invention relates to the technical field of biomedicine, and provides application of combination of bacteriophage and antibiotic in preparation of a drug-resistant bacterial infection drug, the bacteriophage is acinetobacter baumannii or mycobacterium tuberculosis bacteriophage, and the antibiotic comprises one or more of amikacin, fosfomycin and polymyxin B. The invention provides the application of the combination of the bacteriophage and the antibiotic in the aspect of preparing the drug-resistant bacterial infection drug, the synergistic interaction can be realized, the drug resistance is reduced, the bacteriocidal spectrum is expanded, and the support is provided for the early intervention, accurate effect generation and prognosis improvement of the drug-resistant bacterial infection.